Education
About Us
Working with TipRanks
Follow Us
Amgen (AMGN)
NASDAQ:AMGN
AMGN Stock Chart & Stats
$303.33
-$0.21(-0.08%)
At close: 4:00 PM EST
$303.33
-$0.21(-0.08%)
Day’s Range― - ―
52-Week Range$253.30 - $335.88
Previous CloseN/A
Volume614.18K
Average Volume (3M)2.56M
Market Cap
$160.87B
Enterprise Value$199.23B
Total Cash (Recent Filing)$8.03B
Total Debt (Recent Filing)$56.20B
Price to Earnings (P/E)24.4
Beta0.45
Next Earnings
Nov 04, 2025EPS Estimate
5.04Last Dividend Ex-Date
Aug 22, 2025Dividend Yield3.1%
Share Statistics
EPS (TTM)6.02
Shares Outstanding538,361,900
10 Day Avg. Volume2,042,315
30 Day Avg. Volume2,560,071
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.24
Enterprise Value/Revenue5.71
Enterprise Value/Gross Profit8.85
Enterprise Value/Ebitda12.53
Forecast
1Y Price Target
$323.38Price Target Upside6.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAMGN reported earnings per share significantly above consensus expectations, leading to an increase in full-year 2025 earnings guidance.
Product DemandAmgen's rare disease portfolio and Imdelltra showed strong demand, contributing to the company's positive financial results.
Regulatory ApprovalRepatha's label was approved for use in adults at increased risk for major adverse cardiovascular events, broadening its reach into the primary prevention space.
Bears Say
Market CompetitionLong-term Repatha risks remain, with anticipated Medicare Part D IRA price controls and potential biosimilar competition after loss of exclusivity.
Product PerformanceSales of Enbrel significantly underperformed compared to consensus expectations, negatively impacting the overall sales figures.
Research And DevelopmentThere is concern over increasing R&D expenses related to obesity, which could affect future margins and EPS.
Amgen News
AMGN FAQ
What was Amgen’s price range in the past 12 months?
Amgen lowest stock price was $253.30 and its highest was $335.88 in the past 12 months.
What is Amgen’s market cap?
Amgen’s market cap is $160.87B.
When is Amgen’s upcoming earnings report date?
Amgen’s upcoming earnings report date is Nov 04, 2025 which is in 14 days.
How were Amgen’s earnings last quarter?
Amgen released its earnings results on Aug 05, 2025. The company reported $6.02 earnings per share for the quarter, beating the consensus estimate of $5.281 by $0.739.
Is Amgen overvalued?
According to Wall Street analysts Amgen’s price is currently Undervalued.
Does Amgen pay dividends?
Amgen pays a Quarterly dividend of $2.38 which represents an annual dividend yield of 3.1%. See more information on Amgen dividends here
What is Amgen’s EPS estimate?
Amgen’s EPS estimate is 5.04.
How many shares outstanding does Amgen have?
Amgen has 538,361,900 shares outstanding.
What happened to Amgen’s price movement after its last earnings report?
Amgen reported an EPS of $6.02 in its last earnings report, beating expectations of $5.281. Following the earnings report the stock price went down -5.133%.
Which hedge fund is a major shareholder of Amgen?
Currently, no hedge funds are holding shares in AMGN
Amgen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$323.38 (6.61% Upside)
$323.38 (6.61% Upside)
Blogger Sentiment
Bullish
AMGN Sentiment 81%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 2.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 7.2%
Last 30 Days ▲ 7.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.89%
12-Months-Change
Fundamentals
Return on Equity
99.14%
Trailing 12-Months
Asset Growth
-3.31%
Trailing 12-Months
Company Description
Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
AMGN Company Deck
AMGN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Amgen's Q2 2025 earnings call highlighted strong revenue and volume growth, driven by significant increases in sales of key products and a robust rare disease portfolio. The company also demonstrated progress in its R&D pipeline. However, challenges remain with pricing pressures and regulatory changes. Despite these challenges, the positive aspects of the call outweigh the negatives.View all AMGN earnings summariesAMGN Revenue Breakdown
13.09% Prolia
9.92% Enbrel
6.66% XGEVA
6.65% Repatha
63.69% Other
AMGN Stock 12 Month Forecast
Average Price Target
$323.38
▲(6.61% Upside)
Technical Analysis
Ownership Overview
0.19% Insiders
24.64% Mutual Funds
0.58% Other Institutional Investors
45.93% Public Companies and Individual Investors